Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib

Lung Cancer

Volumn 60, Issue 3, 2008, Pages 452-454

  Zampa, Germano ^a   Moscato, Michele ^a   Brannigan, Brian W ^b   Morabito, Alessandro ^c   Bell, Daphne W ^b   Normanno, Nicola ^c,d  

^a San Paolo General Hospital   (Italy)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d CROM ^*  (Italy)

Author keywords

Bone marrow stromal cells; Bone metastases; EGFR; Gefitinib; NSCLC; Osteoclast

Indexed keywords

CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GEMCITABINE; PACLITAXEL; ZOLEDRONIC ACID;

ADULT; ARTICLE; BACKACHE; BODY REGIONS; BONE METASTASIS; BONE SCINTISCANNING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SIZE; CASE REPORT; DISEASE COURSE; HUMAN; LABORATORY TEST; LUNG ADENOCARCINOMA; LUNG LOBECTOMY; LUNG METASTASIS; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; RECOMBINANT INBRED STRAIN; SURGICAL TECHNIQUE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOPLASM RECURRENCE, LOCAL; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 44449156529     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.11.002     Document Type: Article

References (15)

1. Coleman R.E. Skeletal complications of malignancy. Cancer 80 (1997) 1588-1594
2. Cohen M.Z., Easley M.K., Ellis C., Hughes B., Ownby K., Rashad B.G., et al. Cancer pain management and the JCAHO's pain standards: an institutional challenge. J Pain Symptom Manage 25 (2003) 519-527
3. Di Maio M., Gridelli C., Normanno N., Perrone F., and Ciardiello F. Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. J Cell Physiol 205 (2005) 355-363
4. Sharma S.V., Bell D.W., Settleman J., and Haber D.A. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7 (2007) 169-181
5. Garfield D. Increasing osteoblastic lesions as a manifestation of a major response to gefitinib. J Thorac Oncol 1 (2006) 859-860
6. Albain K.S.E.R., Gradishar W.J., Hayes D.F., Rowinsky E., Hudis C., Pusztai L., Tripathy D., Modi S., and Rubi S. Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Res Treat 76 (2002) S33
7. von Minckwitz G., Jonat W., Fasching P., du Bois A., Kleeberg U., Luck H.J., et al. A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer. Breast Cancer Res Treat 89 (2005) 165-172
8. Sequist L.V., Bell D.W., Lynch T.J., and Haber D.A. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25 (2007) 587-595
9. Roodman G.D. Biology of osteoclast activation in cancer. J Clin Oncol 19 (2001) 3562-3571
10. Normanno N., De Luca A., Aldinucci D., Maiello M.R., Mancino M., D'Antonio A., et al. Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocr Relat Cancer 12 (2005) 471-482
11. Angelucci A., Gravina G.L., Rucci N., Millimaggi D., Festuccia C., Muzi P., et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 13 (2006) 197-210
12. Zhu J., Jia X., Xiao G., Kang Y., Partridge N.C., and Qin L. Implications for osteolytic bone metastases. J Biol Chem 282 (2007) 26656-26664
13. Kim S.J., Uehara H., Karashima T., Shepherd D.L., Killion J.J., and Fidler I.J. Blockade of epidermal growth factor receptor signaling in tumor cells and tumor-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clin Cancer Res 9 (2003) 1200-1210
14. Weber K.L., Doucet M., Price J.E., Baker C., Kim S.J., and Fidler I.J. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63 (2003) 2940-2947
15. Li Y.Y., Chang J.W., Chou W.C., Liaw C.C., Wang H.M., Huang J.S., et al. Zoledronic acid is unable to induce apoptosis, but slows tumor growth and prolongs survival for non-small-cell lung cancers. Lung Cancer (2007)